Tezspire FDA Approval History
Last updated by Judith Stewart, BPharm on Dec 20, 2021.
FDA Approved: Yes (First approved December 17, 2021)
Brand name: Tezspire
Generic name: tezepelumab-ekko
Dosage form: Injection
Company: Amgen and AstraZeneca
Treatment for: Asthma
Tezspire (tezepelumab-ekko) is a thymic stromal lymphopoietin (TSLP) blocker, human monoclonal antibody (IgG2λ), indicated for the add-on maintenance treatment of adult and pediatric patients aged 12 years and older with severe asthma.
- Tezspire works by inhibiting the action of TSLP, a cytokine that is released in response to triggers associated with asthma exacerbations.
- Tezspire is the only biologic approved for severe asthma with no phenotype (e.g. eosinophilic or allergic) or biomarker limitation within its approved label.
- Tezspire is administered via subcutaneous injection once every four weeks.
- Common adverse reactions include pharyngitis, arthralgia, and back pain.
- Tezspire is also in development for other potential indications including chronic obstructive pulmonary disease, chronic rhinosinusitis with nasal polyps, chronic spontaneous urticaria and eosinophilic esophagitis (EoE).
Development timeline for Tezspire
Date | Article |
---|
Feb 2, 2023 | Approval Tezspire Approved for Self-Administration in the U.S. With a New Pre-filled Pen |
Dec 17, 2021 | Approval FDA Approves Tezspire (tezepelumab) for Severe Asthma |
Oct 8, 2021 | Tezepelumab Granted Orphan Drug Designation in the US for Eosinophilic Esophagitis |
Sep 5, 2021 | New Tezepelumab Data Show 86% Reduction In Exacerbations In Patients With Severe Asthma And Comorbid Nasal Polyps |
Jul 7, 2021 | Tezepelumab Granted Priority Review By U.S. FDA |
May 13, 2021 | New Tezepelumab Data Continue To Strengthen Profile For A Broad Population Of Severe Asthma Patients |
May 10, 2021 | Amgen Announces Tezepelumab Biologics License Application Submitted To U.S. FDA |
Feb 26, 2021 | Tezepelumab is the First Biologic to Consistently and Significantly Reduce Exacerbations in Broad Population of Severe Asthma Patients |
Dec 21, 2020 | Update On SOURCE Phase 3 Trial For Tezepelumab In Patients With Severe, Oral Corticosteroid-Dependent Asthma |
Nov 10, 2020 | Tezepelumab NAVIGATOR Phase III Trial Met Primary Endpoint of a Statistically Significant and Clinically Meaningful Reduction in Exacerbations in a Broad Population of Patients with Severe Asthma |
Nov 9, 2020 | Tezepelumab NAVIGATOR Phase 3 Trial Met Primary Endpoint Of A Statistically Significant And Clinically Meaningful Reduction In Exacerbations In A Broad Population Of Patients With Severe Asthma |
Sep 6, 2018 | Tezepelumab Granted Breakthrough Therapy Designation By US FDA For The Treatment Of Patients With Severe Asthma Without An Eosinophilic Phenotype |
Sep 6, 2017 | Tezepelumab Significantly Reduced Asthma Exacerbations For A Broad Population Of Patients With Severe Uncontrolled Asthma |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Medical Disclaimer